Cover Image
市場調查報告書

間質幹細胞:進步及應用

Mesenchymal Stem Cells - Advances & Applications

出版商 BIOINFORMANT WORLDWIDE, LLC 商品編碼 234291
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
間質幹細胞:進步及應用 Mesenchymal Stem Cells - Advances & Applications
出版日期: 2015年11月23日 內容資訊: 英文 250 Pages
簡介

本報告以間質幹細胞 (MSC) 研究的近幾年的進步為焦點,提供細胞療法產業概要,各適應症的開發中細胞療法產品分析,市售的細胞療法產品,MSC的生物學的特性,幹細胞市場概要,及主要企業簡介,為您概述為以下內容。

第1章 概要

第2章 簡介

第3章 細胞療法產業:概要

  • 細胞療法採用的幹細胞的種類
  • 細胞療法產品的候補:後期臨床開發階段
  • 細胞療法產品的候補:早期臨床開發階段
  • 開發中的細胞療法產品:心血管疾病
  • 開發中的細胞療法產品:中樞神經系統疾病
  • 開發中的細胞療法產品:創傷護理
  • 開發中的細胞療法產品:脊椎、整形外科
  • 開發中的細胞療法產品:糖尿病
  • 開發中的細胞療法產品:自體免疫疾病
  • 組合開發中的細胞療法、遺傳基因療法的產品
  • 活用細胞療法、免疫療法的組合的癌症計劃
  • 主要的市售細胞療法產品
  • 在韓國已批准細胞療法產品
  • 細胞療法臨床實驗:概要
  • 15個在階段III的主要細胞療法產品
  • 細胞療法的臨床實驗失敗
  • 臨床導出幹細胞、前驅細胞為基礎的實驗的取樣調查
  • 主要的細胞療法企業與其定位
  • 幹細胞領域的跨國公司 (MNC) 的參與

第4章 間質幹細胞 (MSC) :概要

  • 對治療效果有貢獻的MSC的生物學特性
  • MSC獲得的影響因素
  • MSC的主要的臨床來源
  • 細胞療法臨床實驗的MSC的優勢
  • 在目前臨床實驗中MSC對應的主要疾病

第5章 幹細胞市場概要

  • 全球幹細胞市場:各疾病

第6章 主要企業簡介

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Executive Summary

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications.

The report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine (RM) and cell therapy (CT) industries.

It also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

There is substantial potential for growth within the MSC market, with more than 30,000 scientific publications published about the cell type, more than 400 clinical trials underway worldwide, and Google Trend data showing MSC searches to be approximately twice as common as the next most common adult stem cell type.

Therefore, the main objectives of the report are to consider the following:

  • Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
  • Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
  • Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
  • The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
  • Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and social analytics (metrics from social media sites, search engines, Google Trends, Google Adwords, and more)

Key questions answered in the report are:

(Regenerative Medicine = RM; Cell Therapy= CT)

  • How many companies are currently supporting the regenerative medicine (RM) industry?
  • What is the current regional breakdown of RM industry?
  • How many RM products have been approved?
  • What are the types of diseases are currently being pursued by RM companies?
  • What are the major financial events, partnerships and acquisitions in RM sector?
  • How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
  • What are the major anticipated RM clinical events in 2015-16?
  • What are the major therapeutic opportunities for the big pharma in RM and CT?
  • How many CT product candidates have reached the Phase IIIstage and what are they?
  • What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
  • What are the major commercially available CT products?
  • What is the total number of CT clinical trials at the global level?
  • What are the major cell types used in CT clinical trials?
  • What are the major indications addressed by CT clinical trials?
  • What are the major CT clinical trials that have reached Phase III?
  • How many CT clinical trials failed in the past year and what are they?
  • What are the contributions of MSCs to the cell therapy industry?
  • What are the biological properties of MSCs?
  • What do MSCs get differentiated into?
  • What bioactive molecules do the MSCs secrete?
  • What are the immunomodulatory functions of MSCs?
  • What are the factors impacting the acquisition of MSCs?
  • What are the various sources of MSCs?
  • What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
  • What are the major clinical trials focusing on diabetes using BMMSCs?
  • What are the major clinical trials involving BMMSCs for cardiovascular diseases?
  • What are the major clinical trials focusing on liver diseases by BMMSCs?
  • What are the brain-related diseases addressed by clinical trials using BMMSCs?
  • How many clinical trials are conducted for intestinal diseases using MSCs?
  • What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
  • Number of clinical trials using MSCs derived from Wharton's jelly for various diseases?
  • What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
  • What is the current number of clinical trials using MSCs?
  • How many major clinical trials using MSCs have reached the Phase III?
  • What are the MSCs-based cell therapy products available in the market?
  • What is the current size of the MSC marketplace?

35 leading MSC companies are profiled in this report, including:

  • American Type Culture Collection Inc. (ATCC)
  • Anterogen Co., Ltd.
  • Apceth GmbH & Co. KG
  • BioCardia Inc.
  • BioRestorative Therapies Inc.
  • Bone Therapeutics SA
  • BrainStorm Cell Therapeutics Inc.
  • CellGenix Technologie Transfer GmbH
  • Celprogen Inc.
  • CellTherapies P/L
  • Cesca Therapeutics Inc.
  • Cyagen Biosciences Inc.
  • Cynata Therapeutics Ltd.
  • Cytori Therapeutics Inc.
  • Escape Therapeutics
  • Genlantis
  • Kite Pharma Inc.
  • Life Technologies Corporation
  • Lonza Group Ltd.
  • Medipost Co. Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc.
  • Ocata Therapeutics Inc.
  • Organogenesis Inc.
  • Orthofix International N.V.
  • Osiris Therapeutics Inc.
  • Pluristem Therapeutics Inc.
  • PromoCell
  • Regeneus Ltd.
  • ScienCell Research Laboratories
  • STEMCELL Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Stempeutics Research Pvt. Ltd.
  • TiGenix N.V.
  • Vericel Corporation

Table of Contents

1. EXECUTIVE SUMMARY

2. REPORT OVERVIEW

  • 2. Target Demographic
  • 2. Key Findings
  • 2.3. Statement of the Report
  • 2.4. Purpose
    • 2.4.1. To Survey Recent MSC Advancements
    • 2.4.2. To Provide a Snapshot of the Global MSC Market
  • 2.4. To Assess Opportunities for Commercialization
    • 2.4.4. To Identify Major Market Players and Assess the Competitive Environment
    • 2.4.5. To Identify Existing and Emerging Trends
    • 2.4.6. To Identify Critical Opportunities and Threats within the MSC Market

3. RESEARCH METHODOLOGY

  • 3.1 . Input Sources
  • 3.2. Research & Analysis Methodologies
  • 3.3. Criteria for Identiyfing MSC Market Leaders
    • 3.3.1. Size of Company
    • 3.3.2. Type of Product/Services
    • 3.3.2. Degree of Specialization
    • 3.3.4. Patent Positions
    • 3.3.5. Business Reputation
    • 3.3.6. Financial Strength
    • 3.3.7. Partnerships
    • 3.3.8. Certifications

4. MESENCHYMAL STEM CELL (MSC) DEFINITIONS & NOMENCLATURE

  • 4.1. Definition
  • 4.2. Alternative Nomenclature
    • 4.2.1. Mesenchymal Stem Cell
    • 4.2.2. Marrow Stromal Cell (or Mesenchymal Stromal Cell)
    • 4.2.3. Multipotent Stromal Cell
    • 4.2.4. Colony-Forming Unit-fibroblasts

5. MSC CRITERIA & CHARACTERISTICS

  • 5.1. Discovery
    • (FIGURE) Key Dates in the Discovery of Mesenchymal Stem Cells
  • 5.2. Physical Assessment
  • 5. Functional Attributes
  • 5.4. Benefits of MSCs Relative to Other Stem Cells
    • (FIGURE) Benefits of MSCs Relative to Other Stem Cells
    • 5.4.1. Well-Characterized
    • 5.4.2. Non-Controversial
    • 5.4.3. Diverse Differentiation Potential
    • 5.4.4. Ease of Growth in Culture
    • 5.4.5. Flexible Propagation
    • 5.4.6. Clinically Relevant Volumes
    • 5.4.7. Role as Regulatory Cells
    • 5.4.8. Delivery of Gene Products
    • 5.4.9. Favorable Immune Status
    • 5.4.10. Commercially Available Research Tools

6. MSC ISOLATION SOURCES

  • 6.1. Adult Sources
    • (TABLE) Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
  • 6.2. Fetal Sources
    • (TABLE) Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation

7. COMMERCIAL INTEREST IN MSCs

  • (TABLE) Differentiation Capacity of Mesenchymal Stem Cells
  • 7.1. Cell Types Derived from MSCs
  • 7.2. Therapeutic Potential of MSCs

8. INTRODUCTION TO REGENERATIVE MEDICINE (RM) INDUSTRY

  • 8.1. Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview
  • 8.2. Global Breakdown of Regenerative Medicine (RM) Industry by Region
    • (TABLE) Global Breakdown of RM Companies by Region
    • (FIGURE) Global Breakdown of RM Companies by Region
  • 8.3. Breakdown of Global RM Companies by Type
    • (TABLE) Global Breakdown of RM Companies by Type
  • 8.4. Number of RM Clinical Trials by Phase of Development
    • (TABLE) Number of RM Clinical Trials by Phase
  • 8.5. Major Financial Events in the RM Industry
    • (TABLE) Major Financial Events in RM Industry in 2014
    • (FIGURE) Major Financial Events in RM Industry in 2014
  • 8.6. Major Partnerships and Acquisitions in RM Industry
    • (TABLE) Major Partnerships and Acquisitions in RM Industry in 2014
    • (FIGURE) Major Partnerships and Acquisitions in RM Industry in 2014
  • 8.7. Major Regulatory Milestones in RM Industry
    • (TABLE) Major Regulatory Milestones in RM Industry in 2014
    • (FIGURE) Major Regulatory Milestones in RM Industry in 2014
  • 8.8. Major Pharma and Biotech Companies Active in Advanced Therapies
    • (TABLE) Major Pharma and Biotech Companies Active in Advanced Therapies
    • (TABLE) Areas of Focus Among Large Pharmaceutical and Biotech Companies Involved with Advanced Therapies
  • 8.9. Major Corporate Partnerships in RM Industry
    • (TABLE) Major Corporate Partnerships in RM Industry in 2014
  • 8.10. Anticipated Major RM Clinical Events
    • (TABLE) Anticipated Major RM Clinical Events in 2015

9. INTRODUCTION TO THE STEM CELL THERAPY INDUSTRY

  • 9.1. Types of Stem Cells Used in Cell Therapy
    • 9.1.1. Human Embryonic Stem Cells
    • 9.1.2. Induced Pluripotent Stem Cells
    • 9.1.3. Mesenchymal Stem Cells (MSCs)
    • 9.1.4. Hematopoietic Stem Cells
    • 9.1.5. Adipose Stem Cells (ASCs)
    • 9.1.6. Neural Stem Cells (NSCs)
      • (TABLE) Different Types of Stem Cells Used in Cell Therapy and their Characteristics
  • 9.2. Types of Stem Cells Used in Cell Therapy, by Differentiation Potential
    • (FIGURE) Five Types of Stem Cells, by Differentiation Potential
  • 9.2.1. Totipotent (or Omnipotent) Stem Cells
  • 9.2.2. Pluripotent Stem Cells
  • 9.2.3. Multipotent Stem Cells
  • 9.2.4. Oligopotent stem cells
  • 9.2.5. Unipotent Stem Cells

10. CELL THERAPY (CT) PRODUCTS: SUCCESSES AND FAILURES

  • 10.1. Cell Therapy Product Candidates in Late-Stage Clinical Development
    • (TABLE) Mesenchymal Stem Cell Product Candidates in Late-Stage Clinical Development
  • 10.2. Cell Therapy Products Being Developed for Cardiovascular Indication
  • 10.3. Cell Therapy Products Being Developed for Other Indications
  • 10.4. Major Commercially Available Cell Therapy Products
  • 10.5. Cell Therapy Products Approved in South Korea
    • (TABLE 13) Cell Therapy Products Approved in South Korea
  • 10.6. Major Cell Therapies in Phase III
    • 10.6.1. Prochymal
    • 10.6.2. Mesenchymal Precursor Cell (MPC)
    • 10.6.3. MyoCell
    • 10.6.4. Ixmyelocel-T
    • 10.6.5. ELAD
    • 10.6.6. HP802
    • 10.6.7. StemEx (Carlecortemcel-L)
    • 10.6.8. LaViv
    • 10.6.9. GSK 2696273
    • 10.6.10. Renew
    • 10.6.11. NT-501 (Renexus)
    • 10.6.12. Neocart
    • 10.6.13 DeNovo ET
    • 10.6.14. MACI
  • 10.7. Clinical Trial Failures in Cell Therapy
    • 10.7.1. Failure of Phase II for MultiStem
    • 10.7.2. Failure of Cardio 133 Trial
    • 10.7.3. Termination of AlloCure's ACT-AKI Trial
    • 10.7.4. Failed Stroke Trial in India
    • 10.7.5. Failure of HeartiCellGram-AMI Trial
    • 10.7.6. Failure of Adipose MSCs in ARDS
    • 10.7.7. CD133+ in CLI Not Feasible
    • 10.7.8. Failed MSC Trial for Multiple Sclerosis
    • 10.7.9. Failure of Chinese Diabetes Trial
    • 10.7.10. Failed Efficacy Trial in AMI by Stempeucel
    • 10.7.11. Involvement of Multinational Companies (MNCs) in Cell Therapy Sector
      • (TABLE) Major Companies and Products in Development within Cell Therapy Sector

11. THE MARKET FOR MESENCHYMAL STEM CELL THERAPIES

  • 11.1. Market Potential-All Stem Cell Types
  • 11.2. Market Potential-Mesenchymal Stem Cells
  • 11.3. Global Market for Stem Cells by Disease Indication
    • (TABLE) Global Market for Stem Cell Therapies by Disease Indication, Through 2021
    • (FIGURE) Global Market for Stem Cell Therapies by Disease Indication, Through 2021

12. RESEARCH AND THERAPEUTIC APPLICATIONS OF MSCs

  • (TABLE) MESENCHYMAL STEM CELL RESEARCH APPLICATIONS
  • 12.1. Basic Research Applications
    • 12.1.1. MSC Morphology
    • 12.1.2. MSC Detection
    • 12.1.3. Differentiation Capacity
    • 12.1.4. Immuno-modulatory Effects
  • 12.2. Cell Transplantation for Site-Specific Repair
    • 12.2.1. Osteochondral Repair
    • 12.2.2. Myogenic and Myocardial Repair
    • 12.2.3. Neural Repair
    • 12.2.4. Pancreatic Repair
  • 12.3. Directed Differentiation of Mesenchymal Stem Cells
    • 12.3.1 . Directed Differentiation of MSCs into Intra-Mesenchymal Lineages
    • 12.3.2. Directed Differentiation of MSCs into Extra-Mesenchymal Lineages
  • 12.4. Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs
  • 12.5. Drug Screening
  • 12.6. Gene Transfer Studies
  • 12.7. MSC-Mediated Inhibition of Immune Effector Cells
  • 12.8. Supporting Hematopoietic Cell Applications
  • 12.9. Use of 3-D Scaffolds for Tissue Engineering
  • 12.10. Topical Therapy and Use of MSCs in Wound Healing

13. MSC PRODUCT DEVELOPMENT VARIABLES-ATTRIBUTES & ACQUISITION

  • 13.1. Biological Properties of MSCs Contributing to Therapeutic Effects
    • 13.1.1. MSCs' Capacity to Migrate and Engraft
    • 13.1.2. MSCs' Differentiation Potential
      • (TABLE) Origin and Cell Types Derived from MSCs
    • 13.1.3. MSCs' Potential to Secrete Multiple Bioactive Molecules
      • (TABLE) Important Bioactive Molecules Secreted by MSCs and Their Functions
    • 13.1.4. MSCs' Potential for Immunomodulatory Functions
      • (TABLE) Immunomodulatory Effects of MSCs on Immune Cells
    • 13.1.5. Variable Immunophenotype of MSCs
      • (TABLE) Cell Surface Antigen Expressions of MSCs Isolated from Different Sources
  • 13.2. Factors Impacting MSCs Acquisition
  • 13.3. Major Clinical Sources of MSCs
    • (TABLE) Major Clinical Sources of MSCs

14. CLINICAL APPLICATIONS OF MESENCHYMAL STEM CELLS

  • 14.1. Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
    • 14.1.1. BMMSCs and Kidney
      • (TABLE) A Sample of Clinical Trials using BMMSCs for Kidney Diseases
    • 14.1.2. BMMSCs and Pancreas
      • (TABLE) A Sample of Clinical Trials Using BMMSCs for Diabetes
    • 14.1.3. BMMSCs and Heart
      • (TABLE) A Sample of Clinical Trials Using BMMSCs for Heart Disease
    • 14.1.4. BMMSCs and Liver
      • (TABLE) A Sample of Clinical Trials Using BMMSCs for Liver Diseases
    • 14.1.5. BMMSCs and Brain
      • (TABLE) Clinical and Experimental Therapies Using MSCs for Neural Diseases
    • 14.1.6. BMMSCs and Intestine
      • (TABLE) A Sample of Clinical Trials Using BMMSCs for Intestinal Diseases
    • 14.1.7. BMMSCs and Bone
      • (TABLE) A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases
  • 14.2. Adipose-Derived Mesenchymal Stem Cells (ADSCs)
    • 14.2.1. Clinical Appplicationsof Adipose-Derived Mesenchymal Stem Cells (ADSCs)
      • (TABLE) ADSCs Transplantation in Clinical Trials by Region/Country in Phase III
    • 14.2.2. Selected ADSC Secretomes and their Functions
      • (TABLE) Selected ADSC Secretomes and their Functions
  • 14.3. Mesenchymal Stem Cells (MSCs) Derived from Wharton's Jelly
    • 14.3.1. Clinical Application Properties of WJ-MSCs
    • 14.3.2. Immunoprivileged Status of WJ-MSCs
    • 14.3.3. Clinical Applications of WJ-MSCs
      • (TABLE) A Summary of Clinical Trials Using WJ-MSCs
  • 14.4. Umbilical Cord Blood-Derived MSCs (UCBMSCs)
    • (TABLE) Clinical Trials Using UCBMSCs and Targeted Diseases
  • 14.5. Dominance of MSCs in Cell Therapy Clinical Trials

15. MAJOR DISEASES ADDRESSED BY MSCs IN CURRENT CLINICAL TRIALS

  • (TABLE) Clinical Trials Using MSCs by Disease Type, 2014
  • (FIGURE) Clinical Trials Using MSCs by Disease Type, 2014
  • 15.1. MSCs for Treating Liver Diseases
    • (TABLE) A Sample of Clinical Trials Using MSCs for Liver Disorders
  • 15.2. MSCs for Neurodegenerative Diseases
    • (TABLE): A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases
  • 15.3. Clinical Trials Using MSCs for Autoimmune Diseases
    • (TABLE) A Sample of Phase I and II Clinical Trials for Autoimmune Diseases as of 2012
  • 15.4. Clinical Trials Using MSCs for Diabetes
    • (TABLE) A Sample of Clinical Trials Using MSCs for Diabetes
  • 15.5. MSCs for Cardiovascular Repair
    • (TABLE) A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases
  • 15.6. MSCs for Musculoskeletal Diseases
    • (TABLE) Clinical Trials Involving MSCs for Bone and Cartilage Repair
  • 15.6.1. Studies Using MSCs for Musculoskeletal Indications by Leading Countries
    • (TABLE) Studies Using MSCs for Musculoskeletal Indications by Country
  • 15.6.2. Application of MSCs in Joint Diseases
    • (TABLE) A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
    • (TABLE) A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair
  • 15.7. MSCs in Neuron/Spinal Cord Diseases
    • (TABLE) Sample of Clinical Trials in Different Countries Using MSCs for Neuron and Spinal Cord Diseases
  • 15.8. MSC Infusion for GvHD
    • (TABLE) Clinical Experience of MSCs in GvHD Treatment
  • 15.9. MSCs for Crohn's Disease
    • (TABLE) A Sample of Clinical Trials Using MSCs for Crohn's Disease
  • 15.10. MSCs in Wound Healing
    • (TABLE) Clinical Studies using MSCs for Wound Healing
  • 15.11. Increasing Focus on Immunological Properties of MSCs
    • (TABLE) Number of MSC Scientific Publications about Immune/Inflammation by Year
    • (FIGURE) Number of MSC Scientific Publications about Immune/Inflammation by Year
  • 15.12. Selected MSCs Late-Stage Pipeline Cell Therapies
    • (TABLE) Selected MSCs Late-Stage Pipeline Cell Therapies

16. MARKET OPPORTUNITIES FOR BIOBANKING OF MESENCHYMAL STEM CELLS

  • 16.1. Types of Mesenchymal Stem Cell Biobanking
    • (TABLE) Types of Mesenchymal Stem Cell Biobanking
  • 16.2. Dental Stem Cell Banking (MSC Biobanking)
    • (TABLE) Companies Offering Dental Stem Cell Storage (Diversified Cord Blood Banks and Specialty Companies)
  • 16.3. Umbilical Cord Tissue (MSC Biobanking)
    • 16.3.1. Definitions
    • 16.3.2. Cord Tissue Market Overview
    • 16.3.3. Comparison of Cord Blood & Cord Tissue Storage
      • (FIGURE) Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
    • 16.3.4. Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
      • (TABLE) Medical Conditions Being Investigated for Potential to be Treated with Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
    • 16.3.5. Market Penetration of Cord Tissue within the U.S
      • (TABLE) U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013
      • (TABLE) U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015
    • 16.3.6. Pricing of Cord Tissue Storage (Global Analysis)
      • (TABLE) Pricing Structures for Cord Tissue Storage
  • 16.4. Adipose-Derived MSCStorage
    • (TABLE) Companies Offering Adipose-Derived MSC Storage (Both Diversified Cord Blood Banks and Specialty Companies)
  • 16.5. Other Types of MSCBio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More

17. KEY MARKET METRICS FORF MSCs

  • 17.1. Global Breakdown of Mesenchymal Stem Cell Clinical Trials
    • 17.1.1. Breakdown of MSC Clinical Trials, By Phase
      • FIGURE: Percentage of Mesenchymal Stem Cell (MSC) Clinical Trials by Phase
    • 17.1.2. Additional Resources
    • 17.1.2. Breakdown of MSC Clinical Trials, By Geography
      • (FIGURE) Geographical Assessment of MSC Clinical Trial Activity
      • (TABLE) Geographical Breakdown of MSC Clinical Trial Activity
    • 17.1.3. Types of Sponsoring/Collaborating Organizations Supporting MSC Clinical Trials
      • (TABLE) Breakdown of MSC Clnical Trial Activity by Sponsoring/Collaborating Organization
      • (FIGURE) Breakdown of MSC Clinical Trial Activity by Sponsor/Collaborating Organization
    • 17.1.4. Specific Industry Participants Supporting MSC Clinical Trial Activity
      • (TABLE) Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
      • (TABLE) Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
      • (FIGURE) Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
    • 17.1.5. Summary of Findings for Mesenchymal Stem Cell Clinical Trials
  • 17.2. Patent Analysis
    • 17.2.1. Role of Patent Analysis for Competitive Intelligence
    • 17.2.2. MSC Patent Landscape
    • 17.2.3. Methodology of MSC Patent Analysis
  • 17.2. MSC Patents Filed in 2015
    • (TABLE) Mesenchymal Stem Cell Patents Filed in 2015
  • 17.3. Scientific Publication Analysis
    • (TABLE) Analysis of MSC Scientific Publications per Year
    • (FIGURE) Analysis of MSC Scientific Publications per Year
    • (FIGURE) 5-Year Projections for MSC Scientific Publication Rates (2016-2020)
  • 17.4. Grant Rate Analysis
    • 17.4.1. All-Time Analysis of MSC Grants (1997 to Present)
      • (TABLE) Number of MSC Grant Rates, by Year (RePORTer Analysis)
    • 17.4.1.1. Year-over-Year Trends in MSC Grants
      • (TABLE) Number of MSC Projects Funded by NIH Support by Year
      • (TABLE) Amount of Funding for MSC Projects Supported by NIH by Year
    • 17.4.1.2. Geographical Assessment of MSC Grants
      • (TABLE) Geographical Assessment of MSC Grants Funded by NIH Support
    • 17.4.1.3. Assessment of MSC Grants By Subject Matter (1997 to Present)
      • (GRAPH) Breakdown of MSC Grants Funded by NIH Suppport by Subject Matter
    • 17.4.1.4. Dominant Principal Investigators
      • (TABLE) Leading Principal Investigators for MSC Research
    • 17.4.2. 2015 Analysis of MSC Grants
      • 17.4.2.1. List of MSC Grants Funded by NIH-Support in 2015 Fiscal Year
        • (TABLE) MSC Grants Funded by NIH-Support in 2015 Fiscal Year
      • 17.4.2.2. Assessment of MSC Grants by Subject Matter (2015)
        • (TABLE) Breakdown of MSC Grants Funded by NIH-Support by Subject

18. SOCIAL ANALYTICS FOR MESENCHYMAL STEM CELLS

  • 18.1. Marketing Cost Analysis: Search Term “Mesenchymal Stem Cell”
    • 18.1.1. Pay-Per-Click Cost for the Search Term “Mesenchymal Stem Cell”
      • (FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; U.S. Only)
      • (FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; U.S. Only)
      • (FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; Geography: Worldwide)
      • (FIGURE) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; Geography: Worldwide)
      • (TABLE) Google Adwords Pay-Per-Click (PPC) Costs for MSCs
    • 18.1.2. Analysis of Derivative Search Terms
      • (FIGURE) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: USA Only)
      • (FIGURE) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: Worldwide)
  • 18.2. MSC Articles Receiving Most Social Media Shares over Past 12 Months
    • 18.2.1. MSC Specific Analysis
      • (TABLE) Most Shared MSC Articles of the Past 12 Months
    • 18.2.1. Stem Cell Analysis (All Types)
      • (TABLE) Most Shared Stem Cell Articles of the Past 12 Months (All Stem Cell Types)
  • 18.3. Google Trend Data for MSCs
    • 18.3.1. Google Trend Data - Mesenchymal Stem Cells Only
      • (FIGURE) Comparison of Google Trend Data for “Mesenchymal Stem Cells” (Plural) vs. “Mesenchymal Stem Cell” (Singular) over a 10-Year History
      • (FIGURE) Google Trend Data for “Mesenchymal Stem Cells” over a 5-Year History
      • (FIGURE) Google Trend Data Showing Regional Interest in “Mesenchymal Stem Cells” over a 5-Year History
      • (GRAPH) Google Trend Data Showing City-by-City Interest in “Mesenchymal Stem Cells” over a 5-Year History
      • (TABLE) Google Trend Data Showing Related Searches for “Mesenchymal Stem Cells” over a 5-Year History
      • (FIGURE) Groundbreaking Years in Hematopoietic Stem Cell Transplant History
    • 19.3.2. Google Trend Data-All Types of Stem Cells
      • (FIGURE) Google Trend Data for “Stem Cells” over a 10-Year History
      • (FIGURE) Google Trend Data-Comparison of All Types of Stem Cells over a 5-Year History
      • (FIGURE) Google Trend Data Showing Regional Interest in “Stem Cells” over a 5-Year History
      • (FIGURE) Google Trend Data Showing City-by-City Interest in “Stem Cells” over a 5-Year History
      • (TABLE) Google Trend Data Showing Related Searches for “Stem Cells” over a 5-Year History
  • 18.4. Twitter Hashtag Data
    • (TABLE) Rates of Twitter Usage by Country
  • 18.4.1. Twitter Hashtag Data-Mesechymal Specific Data
    • (FIGURE) Top 10 Hashtags Related to “#Mesenchymal” on Twitter
    • (TABLE) Top 10 Hashtags Related to “#Mesenchymal” on Twitter
  • 18.4.2. Twitter Hashtag Data-Stem Cells (All Types)
    • (FIGURE) Top 10 Hashtags Related to “#StemCells” on Twitter
    • (TABLE) Top 10 Hashtags Related to “#StemCells” on Twitter
  • 18.4.3. Top Five MSC Influencers on Twitter
    • (TABLE) Top 5 MSC Influencers on Twitter
  • 18.4.4. Top Five Stem Cell Influencers on Twitter
    • (TABLE) Top Five Stem Cell Influencers on Twitter

19. SELECTED COMPANY PROFILES

  • 19.1. American Type Culture Collection Inc. (ATCC)
  • 19.2. Anterogen Co., Ltd
    • 19.2.1. Cupistem Injection
    • 19.2.2. Queencell
  • 19.3. Apceth GmbH & Co. KG
    • 19.3.1. Apceth's Research Areas
  • 19.4. BioCardia Inc.
    • (TABLE) BioCardia's Product Pipeline Overview
  • 19.5. BioRestorative Therapies Inc
    • 19.5.1. brtxDISC
    • 19.5.2. ThermoStem
  • 19.6. Bone Therapeutics SA
    • 19.6.1. PREOB
    • 19.6.2. ALLOB
      • (TABLE) Bone Therapeutics' Product Pipeline
  • 19.7. BrainStorm Cell Therapeutics Inc
    • 19.7.1. NurOwn
  • 19.8. CellGenix Technologie Transfer GmbH
  • 19.9. Celprogen Inc
  • 19.10. CellTherapies P/L
    • 19.10.1. Services
    • 19.10.2. Product
  • 19.11. Cesca Therapeutics Inc
    • 19.11.1. Surgwerks
    • 19.11.2. Cellwerks
    • 19.11.3. AutoXress (AXP)
    • 19.11.4. MarrowXpress (MXP)
    • 19.11.5. Res-Q BMC
  • 19.12. Cyagen Biosciences Inc
    • 19.12.1. Mesenchymal Stem Cells from Cyagen
      • (TABLE) Cyagen's Mesenchymal Cells
    • 19.12.2. Adipose-Derived Mesenchymal Stem Cells from Cyagen
      • (TABLE) Cyagen's Adipose-Derived MSCs
    • 19.12.3. Mesenchymal Stem Cells with GFP from Cyagen
      • (TABLE) Gyagen's MSCs with GFP
    • 19.12.4. Adipose-Derived Mesenchymal Cells with GFP from Cyagen
      • (TABLE) Adipose-Derived Mesenchymal Cells with GFP
    • 19.12.5. Stem Cell Culture Media from Cyagen
      • (TABLE) Cyagen's Stem Cell Culture Media
    • 19.12.6. Stem Cell Differentiation Media from Cyagen
      • (TABLE) Cyagen's Stem Cell Differentiation Media
    • 19.12.7. Primary Cells from Cyagen
      • (TABLE) Primary Cells from Cyagen
    • 19.12.8. Cyagen's Cryopreservation Media
      • (TABLE) Cyagen's Cryopreservation Media
    • 19.12.9. Cyagen's Primary Cell Culture Media
      • (TABLE) Cyagen's Primary Cell Culture Media
    • 19.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen
      • (TABLE) General Cell Culture Supplements and Specialty Reagents from Cyagen
  • 19.13. Cynata Therapeutics Ltd
    • 19.13.1. Cymerus Platform Technology
  • 19.14. Cytori Therapeutics Inc
    • 19.14.1. Clinical Trial for Scleroderma
    • 19.14.2. Clinical Trials for Osteoarthritis
  • 19.15. Escape Therapeutics
    • (TABLE) Escape Therapeutics' Pipeline Products
  • 19.16. Genlantis
  • 19.17. Kite Pharma Inc
    • 19.17.1. Engineered Autologous Cell Therapy (eACT)
    • 19.17.2. DC-Ad GM-CAIX
      • (TABLE) Kite Pharma's Pipeline and Clinical Trials
  • 19.18. Life Technologies Corporation
  • 19.19. Lonza Group Ltd
    • 19.19.1 Selected Products
  • 19.20. Medipost Co. Ltd
    • 19.20.1. Cartistem
    • 19.20.2. Neurostem
    • 19.20.3. Pneumostem
  • 19.21. Mesoblast Ltd
    • 19.21.1. Mesoblast's Product Pipeline Overview
      • (TABLE) Mesoblast's Product Pipeline Overview
  • 19.22. NuVasive Inc
    • 19.22.1. Osteocel
  • 19.23. Ocata Therapeutics Inc
    • (TABLE) Ocata's Pipeline of Therapeutic Programs
  • 19.24. Organogenesis Inc
    • 19.24.1. Apligraf
    • 19.24.2. Dermagraft
  • 19.25. Orthofix International N.V
    • 19.25.1. Trinity Elite
    • 19.25.2. Trinity Evolution
  • 19.26. Osiris Therapeutics Inc
    • 19.26.1. Grafix
    • 19.26.2. OvationOS
    • 19.26.3. Cartiform
  • 19.27. Pluristem Therapeutics Inc
    • 19.27.1. PLX Cells
  • 19.28. PromoCell
  • 19.29. Regeneus Ltd
    • 19.29.1. Products
      • (TABLE) Regeneus' Product Pipeline
  • 19.30. ScienCell Research Laboratories
  • 19.31. STEMCELL Technologies Inc
  • 19.32. Stemedica Cell Technologies Inc
    • 19.32.1. Stemedyne MSC
    • 19.32.2. Stemedyne NSC
    • 19.32.3. Stemedyne RPE
  • 19.33. Stempeutics Research Pvt. Ltd
    • 19.33.1. Stempeucel
    • 19.33.2. Stempeutron
    • 19.33.3. Stempeucare
      • (TABLE) Stempeucel in Clinical Trials by Indication
  • 19.34. TiGenix N.V
    • 19.34.1. Cx601
    • 19.34.2. Cx611
    • 19.34.3. Cx621
  • 19.35. Vericel Corporation
    • (TABLE) Vericel Corporation's Product Portfolio
    • (TABLE) Summary Table for the Companies and Their Product Types
Back to Top